GLP-1 Drugs Face Backlash Over Trump’s ‘Fat Shots’ Label and a Health-Stigma Debate

Trump’s nickname for GLP-1 medications—calling them 'fat shots'—has sparked backlash from doctors and patients who say GLP-1s are life-changing for diabetes, obesity and heart health. As usage climbs nationwide and Trump seeks to lower costs, critics warn the label fuels obesity stigma and understates the drugs’ medical benefits and access barriers, including Medicaid coverage. The piece underscores the tension between political rhetoric and public health, urging focus on access and accurate understanding of obesity as a complex disease.